Page 472 - ILAE_Lectures_2015

25. ANNEGERS JF, COAN SP, HAUSER WA, LEESTMA J (2000) Epilepsy, vagal nerve stimulation by the
NCP system, all-cause mortality, and sudden, unexpected, unexplained death. Epilepsia 41(5), 549-553.

26. GRANBICHLER CA, NASHEF L, SELWAY R, POLKEY CE (2015) Mortality and SUDEP in epilepsy
patients treated with vagus nerve stimulation Epilepsia 56(2), 291-296.

27. BEN-MENACHEM E, HELLSTROM K, VERSTAPPEN D (2002) Analysis of direct hospital costs before
and 18 months after treatment with vagus nerve stimulation therapy in 43 patients. Neurology 59 (Suppl 4),
S44-S47.

28. BOON P, D'HAVE M, VAN WALLEGHEM P et al (2002) Direct medical costs of refractory epilepsy incurred
by three different treatment modalities: a prospective assessment. Epilepsia 43(1), 96-102.

29. HELMERS SL, DUH MS, GUÉRIN A et al (2011) Clinical and economic impact of vagus nerve stimulation
therapy in patients with drug-resistant epilepsy. Epilepsy Behav 22, 370-375.

30. ZEILER FA, ZEILER KJ, TEITELBAUM J, GILLMAN LM et al (2015) VNS for refractory status epilepticus.
Epilepsy Res 112, 100-113.

31. CERSOSIMO RO, BARTULUCHI M, DE LOS SANTOS C et al (2011) Vagus nerve stimulation:
effectiveness and tolerability in patients with epileptic encephalopathies. Childs Nerv Syst 27(5), 787-792.

32. KLINKENBERG S, VAN DEN BOSCH CN, MAJOIE HJ et al (2013) Behavioural and cognitive effects
during vagus nerve stimulation in children with intractable epilepsy - a randomized controlled trial. Eur J
Paediatr Neurol 17(1), 82-90.

33. RONG P, LIU A, ZHANG J, WANG Y et al (2014) Transcutaneous vagus nerve stimulation for refractory
epilepsy: a randomized controlled trial. Clin Sci (Lond), Apr 1 (Epub ahead of print).

34. AIHUA L, SU L, LIPING L, XIURU W et al (2014) A controlled trial of transcutaneous vagus nerve
stimulation for the treatment of pharmacoresistant epilepsy Epilepsy Behav 39, 105-110.